Accrufer FDA Approval History
Last updated by Judith Stewart, BPharm on Sep 26, 2019.
FDA Approved: Yes (First approved July 25, 2019)
Brand name: Accrufer
Generic name: ferric maltol
Dosage form: Capsules
Previous Name: Feraccru
Company: Shield Therapeutics plc
Treatment for: Iron Deficiency
Accrufer (ferric maltol) is a non-salt formulation of ferric iron for the treatment of iron deficiency in adults.
- Accrufer capsules are taken twice daily on an empty stomach, at least one hour before or two hours after meals.
- Accrufer may decrease the the bioavailability of some oral medications and administration times may need to be separated. Concomitant use with dimercaprol should be avoided.
- Common adverse reactions (incidence >1%) include flatulence, diarrhea, constipation, discolored feces, abdominal pain, nausea, vomiting, and abdominal discomfort or bloating.
Development timeline for Accrufer
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
